Attached files
| file | filename |
|---|---|
| EX-99.1 - SETTLEMENT AGREEMENT - BioCorRx Inc. | bicx_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): June 3, 2014
BioCorRx Inc.
(Exact name of registrant as specified in its charter)
333-153381
(Commission File Number)
|
Nevada
|
26-1972677
|
|
|
(State or other jurisdiction of Incorporation)
|
(I.R.S. Employer Identification No.)
|
601 N. Parkcenter Drive, Suite 103
Santa Ana, California 92705
(Address of principal executive offices)
(714) 462-4880
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Item 1.01 Entry into a Material Definitive Agreement.
On June 3, 2014, BioCorRx Inc., a Nevada corporation (the "Company"), entered into a Settlement Agreement (the “Agreement”) with Fresh Start Private Florida, LLC (“FSP Florida”) and Timothy Jon Jackoboice (“Jackoboice”). The Agreement provided, among other things, the following:
|
(i)
|
the Company shall * release any and all causes of action against FSP Florida and Jackoboice in exchange for release from FSP Florida and Jackoboice of any and all causes of action against the Company, and
|
|
(ii)
|
the License Agreement entered into by the Company and FSP Florida on January 27, 2012 is null and void, thereby allowing the Company to regain the exclusive right to receive, implant, use, sell and otherwise commercialize the Naltrexone implant product and the Start Fresh Program throughout the State of Florida.
|
The foregoing text of this Item 1.01 is qualified in its entirety by the Agreement, attached hereto as Exhibit 99.1. The terms of the Agreement are incorporated by reference herein.
*Information omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are furnished as part of this Form 8-K:
| Exhibit 99.1 | Settlement Agreement dated June 3, 2014.* |
*A portion of Exhibit 99.1 has been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOCORRX INC. | |||
|
Date: June 9, 2014
|
By: |
/s/ Lourdes Felix
|
|
|
Lourdes Felix
Chief Financial Officer and Director
|
|||
3